title: Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
abstract: Granulocyte colony-stimulating factor (G-CSF) effectively mobilises haematopoietic stem cells to the peripheral blood. It is unclear whether the mobilisation of stem cells with lenograstim (glycosylated G-CSF) or filgrastim (non-glycosylated G-CSF) leads to a higher cell number of collected engraft able progenitor cells. Thus, we investigated harvesting efficiency of the licensed G-CSF preparations in mobilising peripheral stem cells in a randomised study. A total of 501 healthy unrelated donors, including 339 males and 162 females received either lenograstim (n = 261) or filgrastim (n = 240) at 10 microg/kg body weight (BW) per day. Aphaeresis was performed on day 5 and, if necessary, on day 6 of mobilisation. The number of CD34+ cells collected was 11.5% higher in the lenograstim group (7.19 x 10(6) vs. 6.44 x 10(6)/kg BW donor; P < 0.03). Univariate variance analysis revealed that this effect was caused by male donors: more progenitors cells per kg BW of the donor (7.73 x 10(6) vs. 6.88 x 10(6); P < 0.017) and of the recipient (10.1 x 10(6) vs. 8.88 x 10(6), P < 0.029) could be harvested. There was no significant difference in the percentage of donors in whom a second aphaeresis was required (9.6% vs. 11.6%). Lenograstim mobilises progenitor cells into the peripheral blood more effectively in males than filgrastim.
authors.affiliation: Institute for Transplantation Diagnostics and Cell Therapeutics, University of Düsseldorf Medical School, Düsseldorf, Germany. fischer@itz.uni-duesseldorf.de
authors.forename: Johannes C
authors.initials: JC
authors.lastname: Fischer
authors.forename: Markus
authors.initials: M
authors.lastname: Frick
authors.forename: Ralf
authors.initials: R
authors.lastname: Wassmuth
authors.forename: Alexander
authors.initials: A
authors.lastname: Platz
authors.forename: Michael
authors.initials: M
authors.lastname: Punzel
authors.forename: Peter
authors.initials: P
authors.lastname: Wernet
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D001781:Blood Component Removal; D001835:Body Weight; D002452:Cell Count; D015986:Confounding Factors, Epidemiologic; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D000078224:Lenograstim; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011446:Prospective Studies; D011786:Quality Control; D011994:Recombinant Proteins / Q000494:pharmacology; D017678:Sex Distribution; D013234:Stem Cells / Q000276:immunology; D014019:Tissue Donors
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim